Cognition

Do we have more empathy for people who are similar to us? New research suggests it’s not that simple

Retrieved on: 
Montag, Juni 3, 2024
Emotion, Science, Cognition, Intelligence, Economy, Social, Research, Empathy, Refugee, Cohesion (computer science), Thought, Oscillation, Human, CC BY-SA, Attention, CC, Spectrum, Social Research (journal), Patient, Confusion, City, Industrial design

Social scientists are struggling with these questions because the mental processes underlying social interactions are not well understood.

Key Points: 
  • Social scientists are struggling with these questions because the mental processes underlying social interactions are not well understood.
  • This draws on research looking at people who are known to experience social difficulties, such as autistic people.
  • Meanwhile, other studies are being used as evidence of double empathy despite never having set out to test this theory.
  • That is, being similar in identity to other people does not necessarily mean that you have more empathy for them.
  • * Read more: Increasingly sophisticated AI systems can perform empathy, but their use in mental health care raises ethical questions * *

The benefits of diversity

Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting

Retrieved on: 
Donnerstag, Mai 30, 2024
NDA, FDA, Trauma, Reduction, PTSD, ASD, Week, COVID, ASCP, Therapy, Disability, Infection, Cocaine, Psychiatry, New Drug Application, Sleep, Sumatriptan, ASR, Autoimmunity, CNS, OASIS, Security (finance), Tonix Pharmaceuticals, Military personnel, Insomnia, Food, Safety, Long, Research, Cancer, Fatigue, Annual report, PROMIS, Society, Cognition, Failure, Science, Fibromyalgia, Patient, Risk, Government, Breakthrough therapy, CD40L, Health, Acute stress disorder, Observation, Veteran, Central nervous system, Disease, Annual general meeting, Pharmaceutical industry

CHATHAM, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced two poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 in Miami Beach, Fla. Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.

Key Points: 
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com .
  • TNX-102 SL was well tolerated with an adverse event profile comparable to prior studies and no new safety signals observed.
  • Previous trials of TNX-102 SL showed that it reduced military PTSD symptoms in as early as two weeks with favorable tolerability.
  • Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response.

Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases

Retrieved on: 
Mittwoch, Mai 29, 2024
Neuroscience, FDA, Drug development, Pediatrics, Drug discovery, Distinguishing, Mental health, Research, Therapy, ALS, Pharmacology, Human, Translational research, Ageing, Multiple sclerosis, Myenteric plexus, CNS, Division, Cognition, University, Clinical trial, DSM-IV codes, Regulatory affairs, Genetics, Associate, SAB, Schizophrenia, CIAS, Patient, Organization, NIMH, Duke University Hospital, Biomarker, Abstract, Brain, Deficit spending, Pharmaceutical industry

NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).

Key Points: 
  • NAARDEN, The Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB).
  • "At Kynexis, we are committed to restoring brain function to enable a better life for people with schizophrenia,” said Kees Been, Chief Executive Officer at Kynexis.
  • Robert Schwarcz, Ph.D., is a Scientific Co-founder of Kynexis and Professor of Psychiatry, Pharmacology and Pediatrics at the University of Maryland Baltimore.
  • Based on these insights, he co-founded Kynexis to develop fundamentally new interventions for the prevention and treatment of brain dysfunctions in humans.

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

Retrieved on: 
Mittwoch, Mai 29, 2024
Epilepsy, American Academy, Doctor of Philosophy, SHARP, Memory, Somnolence, University, AASM, Therapy, Sleep Research Society, Assistant, Excessive daytime sleepiness, Sleep, OSA, CNS, EDS, Washington State University, Central nervous system, SRS, Cognition, Function (mathematics), Central Time

“Cognitive functioning is an underappreciated facet of sleep disorders.

Key Points: 
  • “Cognitive functioning is an underappreciated facet of sleep disorders.
  • Often overshadowed by clinically defining symptoms such as EDS, impaired cognition involves significant burden to patient lives.
  • The SHARP study of solriamfetol showed improved cognitive functioning in participants with impaired cognition associated with OSA and EDS,” said Hans Van Dongen, PhD, Professor at Washington State University and presenting author of the SHARP study plenary lecture.
  • Poster Date/Time: Wednesday, June 5 from 11-11:45 a.m. Central Time
    Title: SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Mittwoch, Mai 22, 2024
Security (finance), Sleep, Sumatriptan, Risk, Food, NDA, Disease, University, ASR, FDA, Autoimmunity, Breakthrough therapy, Government, Reduction, Long, CD40L, Research, Cancer, Annual general meeting, CBP, CNS, Fatigue, Annual report, Acute stress disorder, ASCP, Society, Anxiety, Therapy, Infection, Cognition, Failure, Central nervous system, Cocaine, Science, OASIS, Pharmaceutical industry

CHATHAM, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and present two posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 28-31, 2024 at the Loews Miami Beach Hotel in Miami Beach, Fla.

Key Points: 
  • The oral presentation will detail findings of studies of Tonmya (TNX-102 SL, sublingual cyclobenzaprine HCl) in fibromyalgia.
  • One poster will describe the Phase 2 proof of concept study of TNX-102 SL in fibromyalgia-type Long COVID.
  • TNX-102 SL is a centrally acting, non-opioid medication, which is trade named Tonmya™ for the management of fibromyalgia.
  • Copies of the Company’s presentation and posters will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

Retrieved on: 
Dienstag, Mai 21, 2024
Patient, EEG, Protein, Synapse, Conversation, Diagnosis, Therapy, Head, Research, Dementia, Amyloid, Cognition, Medical device

Additionally, the panelists discuss using quantitative electroencephalography (EEG) as a real-time biomarker of synaptic function.

Key Points: 
  • Additionally, the panelists discuss using quantitative electroencephalography (EEG) as a real-time biomarker of synaptic function.
  • Finally, Dr. Hamby summarized results of proteomic analysis demonstrating the impact of CT1812 treatment on proteins and pathways altered in Alzheimer’s disease, namely, synapse, amyloid beta processing and neuroinflammation.
  • Anthony Caggiano, M.D., Ph.D. CMO and head of R&D for Cognition Therapeutics moderates the discussion joined by VP of research, Mary Hamby, Ph.D. and two leading experts:
    Listen to episode eight, “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease” on the Conversations tab of the Cognition website.
  • If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.

Soon You’ll Be Able to Measure and Improve Your Brain Performance, Anytime, Anywhere

Retrieved on: 
Montag, Mai 20, 2024
Patient, NASA, Medicare, Athlete, Education, COVID-19, Exercise, Travel, SAN, Grammatical mood, Attention, Brain, Cognition, Quality of life, Dementia, Memory, Toy

SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- A newly published study showed that it is feasible for people to measure their brain health anywhere, at any time.

Key Points: 
  • SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- A newly published study showed that it is feasible for people to measure their brain health anywhere, at any time.
  • The study looked at 29 assessments of brain performance designed by Posit Science , the maker of the brain health app BrainHQ .
  • “In recent years, we’ve worked with everyone from people with brain fog to people optimizing peak brain performance, such as elite athletes and teams, members of special forces, and even folks at NASA.
  • They all want an easy way to get a baseline measure of brain performance, and then measure changes that occur over time.

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

Retrieved on: 
Mittwoch, Mai 15, 2024
ACT, Plasma, Toxicity, AAN, Investment, Neurodegenerative disease, IND, Ageing, GBA1, Drug development, ADAS, Excitotoxicity, Inflammation, Therapy, ALS, Neurotrophic factors, American Academy, Survival, DSM-IV codes, Conference, Research and development, SHAPE, Administration, Cognition, Food and Drug Administration, Food, Arrowhead Pharmaceuticals, Doctor of Philosophy, Disease, Pathology, Poster, ERP, Central nervous system, Patient, Lewy body, Investigational New Drug, HGF, Treatment, Drug discovery, Biomarker, Frontiers, Dementia, GST, Annual general meeting, Pharmaceutical industry

BOTHELL, Wash., May 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended March 31, 2024, and provided recent pipeline and business updates.

Key Points: 
  • Athira expects to report topline data from LIFT-AD in the second half of 2024.
  • Athira expects to initiate a first-in-human study of ATH-1105 in the second quarter of 2024.
  • R&D expenses were $21.2 million for the quarter ended March 31, 2024, compared to $21.3 million for the quarter ended March 31, 2023.
  • G&A expenses were $6.5 million for the quarter ended March 31, 2024, compared to $8.5 million for the quarter ended March 31, 2023.

Wolters Kluwer supports food-as-medicine research with enhanced nutrition-focused content

Retrieved on: 
Donnerstag, Mai 16, 2024
Software, Research, Pharmaceutical, Data Management, Technology, Fitness & Nutrition, Science, Biotechnology, Alternative Medicine, Practice Management, Health, Diabetes, Pharmacology, Public, Wolters Kluwer, DSM-IV codes, Obesity, Ecosystem, Allergy, Mental health, Chinese, Publishing, Database, Senior, Trust, Medicine, Policy, Diet, Notifiable disease, Multimedia, Cognition, Record, Dietary supplement

Wolters Kluwer Health , in collaboration with International Food Information Service (IFIS Publishing), today announced the launch of an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Ovid NutriHealth).

Key Points: 
  • Wolters Kluwer Health , in collaboration with International Food Information Service (IFIS Publishing), today announced the launch of an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Ovid NutriHealth).
  • View the full release here: https://www.businesswire.com/news/home/20240516573261/en/
    Wolters Kluwer Health and the International Food Information Service launch an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Photo: Business Wire)
    “The convergence of medicine and nutrition continues to be an important, growing trend in patient care and medical research.
  • The availability of verified, evidence-based nutritional medicine information for broader dissemination is crucial in addressing food-related health disparities,” said Rafael Sidi , Senior Vice President & General Manager of Health Research, Wolters Kluwer Health.
  • The collaboration between IFIS Publishing and Wolters Kluwer was built to meet the industry’s evolving information needs due to the growing focus on nutrition in medical education curricula and medical research.

SoluPet Supplement’s Latest Research Reveals a Canine Cognition Crisis Is Coming

Retrieved on: 
Mittwoch, Mai 15, 2024
Health, Veterinary, Pets, Consumer, Human, Hope, Silybum, Science, Risk, Canine cognitive dysfunction, Education, Prevalence, Mental toughness, Ageing, Animal, Research, Veterinarian, Dementia, Nanotechnology, CCD, Dog, Cognition, Multimedia, Pharmaceutical industry

Recent research reveals that a staggering thirty (30) million dogs in the US have visited their vets for cognition concerns, yet viable treatments remain scarce.

Key Points: 
  • Recent research reveals that a staggering thirty (30) million dogs in the US have visited their vets for cognition concerns, yet viable treatments remain scarce.
  • With the surge in dog ownership during the Covid pandemic, the prevalence of Canine Cognitive Dysfunction (CCD) is poised to escalate, demanding urgent attention.
  • This presents a substantial opportunity for SoluPet to meet the growing demand for cognition dog solutions.
  • As the canine cognitive crisis looms large, SoluPet's innovative supplement stands as a beacon of hope for millions of aging dogs and their owners.